

Anti-Complement component C5b-9 (human)**Mouse monoclonal antibody**

Subclass: IgG2a/k

CAT. NO.

DIA 011-01

Clone: aE11

SPECIFICITY	DIA 011-01 binds both membrane-bound MAC (active) and fluid-phase SC5b-9 complexes (inactive) (1).
IMMUNOGEN	Purified C5b-9
TESTED APPLICATIONS	ELISA, WB (not applicable), IHC-F, IHC-P
SPECIES REACTIVITY (POSITIVE)	Human, pig, horse, baboon
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	DIA 011-01 binds to a neoepitope exposed on C9

PRESENTATION

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	10 mM phosphate buffer pH 7.4 containing 0.15 M NaCl and 0.09% sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION

ELISA: DIA 011-01 is well suited for quantifying TCC in ELISA. (2,3)
WB: DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process (4).
IHC: TCC in various tissues by immunohistochemistry (frozen and paraffin sections) (1, 2, 4).
IF: DIA 011-01 can be used in immunofluorescence staining. (5)

TARGET

C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC.

REFERENCES

1. Mollnes TE, Harboe M (1987) Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology. Scand J Immunol 26:381-6
2. Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195
3. Palarasah, Y, Nielsen C, Sprogøe U, Christensen ML, Lillevang S, Madsen HO, Bygum A, Koch C, Skjødt K, Skjøed MO (2011) Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin Exp Immunol 164: 388-395.
4. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8.
5. Jansen J, Høggåsen K, Mollnes T (1993) Extensive Complement Activation in Hereditary Porcine Membranoproliferative Glomerulonephritis Type 11 (Porcine Dense Deposit Disease. Am J Pathol 139: 1356-1365.

This product is not for further manufacture.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.

BioPorto Diagnostics A/S • Tuborg Havnevej 15, st. • DK-2900 Hellerup • Denmark • info@bioporto.com

www.bioporto.com • Phone: +45 4529 0000 • Fax: +45 4529 0001 • CVR/VAT: DK-1864 5882